Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials

prnasiaJune 02, 2021

Tag: Neuren , NNZ-2591 , Phelan-McDermid , Angelman , Pitt Hopkins syndrome

PharmaSources Customer Service